Investigating the use of regorafenib (Stivarga®) in patients with metastatic colorectal cancer (mCRC) after failure of standard therapy (RECORA)
The purpose of the study is to investigate the safety and effectiveness of Stivarga in patients with metastatic colorectal carcinoma in routine use in Germany. The study is purely observational, only data from routine treatment are to be collected. The treatment and treatment conditions are solely at discretion of the treating physician.
No Inclusion Criteria Available
Inclusion Criteria:´ - Male or female patients ≥ 18 years of age with metastatic CRC for whom the decision has been taken by the investigator to treat with Stivarga. - Patients must have signed an informed consent form
Many Locations, Germany
E-mail: [email protected]
Phone: +49 30 300139003
RECORA- Regorafenib in patients with metastatic colorectal cancer (mCRC) after failure of standard therapy.